Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | S100B | P04271 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28756470 | 1.00 | CA2 (0.61) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL1033697 | 1.00 | CA2 (0.61) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL10045762 | 1.00 | CA2 (0.61) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL12416601 | 0.89 | PTGS2 (0.67) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL2455350 | 0.89 | PTGS2 (0.67) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL15347676 | 0.89 | CA2 (0.71) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL11320970 | 0.89 | CA2 (0.71) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL2839684 | 0.89 | CA2 (0.71) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL2455348 | 0.89 | PTGS2 (0.67) | CA2S100BALDH1A1MAPTKDM4E | |
| SCHEMBL20186948 | 0.89 | PTGS2 (0.67) | CA2S100BALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850144-A | Preparation process of ezetimibe | 湖南方盛绿色合成制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-112441959-A | Ezetimibe raw material medicine synthesis process | 石家庄市华新药业有限责任公司 | 2021-03-05 | — | — | CN | claimed |
| CN-115850144-A | Preparation process of ezetimibe | 湖南方盛绿色合成制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115160179-A | Preparation process of ezetimibe intermediate | 湖南方盛堂制药有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3434285-B1 | COMBINATIONS OF OBETICHOLIC ACID AND EZETIMIBE FOR THE TREATMENT OF NAFLD AND NASH | WATERSTONE PHARMACEUTICALS WUHAN CO LTD (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-110818606-B | Preparation method of ezetimibe and intermediate thereof | 上海博志研新药物技术有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-109517316-B | Fluorine-containing active ester, preparation method thereof and resin cured product containing fluorine-containing active ester | 广东莱尔新材料科技股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112441959-A | Ezetimibe raw material medicine synthesis process | 石家庄市华新药业有限责任公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-110818606-A | Preparation method of ezetimibe and intermediate thereof | 上海博志研新药物技术有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190083459-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | WATERSTONE PHARMACEUTICALS(WUHAN) CO., LTD. (CN) | 2019-03-21 | — | — | US | disclosed |
| EP-3434285-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2007-09-06 | — | — | US | disclosed |
| WO-2007072088-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1687287-A1 | A NOVEL PROCESS FOR EZETIMIBE INTERMEDIATE | Hetero Drugs Limited (IN) | 2006-08-09 | — | — | EP | disclosed |
| US-7067675-B2 | Process for ezetimibe intermediate | HETERO DRUGS LIMITED (IN) | 2006-06-27 | — | — | US | disclosed |
| US-20060069137-A1 | Novel process for ezetimibe intermediate | HETERO DRUGS LIMITED (IN) | 2006-03-30 | — | — | US | disclosed |
| US-6992067-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-12-01 | — | — | US | disclosed |
| WO-2005049592-A1 | A NOVEL PROCESS FOR EZETIMIBE INTERMEDIATE | HETERO DRUGS LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB7, NDUFB6 | CA2 4405/4885S100B 3938/4885ALDH1A1 396/4885 |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885S100B 3976/4885ALDH1A1 604/4885 |
| US-20060069137-A1 | Novel process for ezetimibe intermediate | DPP4, NPC1L1, PCSK9 | CA2 2055/4885S100B 4731/4885ALDH1A1 379/4885 |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885S100B 3976/4885ALDH1A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.